Literature DB >> 158571

A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic.

H Maeda, J Takeshita, R Kanamaru.   

Abstract

A lipophilic derivative of neocarzinostatin (NCS), an antitumor antibiotic, was prepared by reaction with a synthetic water-soluble polymer, [(styrene)1 approximately 3-(maleic acid 4 approximately 7/anhydride 1)]. The reaction was carried out at pH 8.6 for 3 h and aimed at modifying the two nonessential amino groups (alpha-amino of Ala-1, epsilon-amino of Lys-20). The NCS-polystyrene (SMANCS) was purified on a column of Sephadex G-100 in 0.05 M ammonium bicarbonate and the main product was obtained as a single peak. The elemental analysis showed an increased C and a decreased N content. U.v. and i.r. absorption spectra for SMANCS showed the presence of styrene. SDS-acrylamide gel electrophoresis at pH 8.5 and the decreased N content suggested a molecular weight of about 25 000, indicating the numbers of polymers conjugated to be about six units, two of which were found attached to the two amino groups. SMANCS was soluble in organic solvents, in contrast to NCS, and in water. SMANCS exhibited increased chemical and biological stability and appeared to possess similar in vitro biological activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158571     DOI: 10.1111/j.1399-3011.1979.tb01730.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  23 in total

1.  Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.

Authors:  Yashveer Singh; Dayuan Gao; Zichao Gu; Shike Li; Stanley Stein; Patrick J Sinko
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

Review 2.  Nanotechnologies for biomedical science and translational medicine.

Authors:  James R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 3.  Polymer nanogels: a versatile nanoscopic drug delivery platform.

Authors:  Reuben T Chacko; Judy Ventura; Jiaming Zhuang; S Thayumanavan
Journal:  Adv Drug Deliv Rev       Date:  2012-02-10       Impact factor: 15.470

4.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Wael Hussein; Tamer Refaat
Journal:  Mol Clin Oncol       Date:  2014-07-23

Review 5.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

Authors:  Mark J Ernsting; Mami Murakami; Aniruddha Roy; Shyh-Dar Li
Journal:  J Control Release       Date:  2013-09-25       Impact factor: 9.776

6.  Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.

Authors:  S Yanai; H Okada; K Saito; Y Kuge; M Misaki; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

7.  Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma.

Authors:  K Jinno; S Moriwaki; M Tanada; T Wada; K Mandai; Y Okada
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy.

Authors:  Huaizhong Pan; Monika Sima; Jiyuan Yang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2013-01-22       Impact factor: 4.979

9.  Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.

Authors:  E Masuda; H Maeda
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin.

Authors:  F Suzuki; R B Pollard; H Maeda
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.